TIME to Talk - Science & Medicine · CFRC Podcast Network

The Cancer CHALLENGE: Exercise Changes the Game – Should We Be Funding Exercise Prescription?

·39 min·3 clips
Exercise reduced colon cancer recurrence by 28% and death risk by 37% in a groundbreaking 20-year study.
Charlie Highmarch and Stephen Archer welcome Chris Booth, a medical oncologist, cancer specialist, and professor at Queen's University. The conversation follows the show's familiar route: start with the dangerous idea, then get to the person behind it. Here, the idea is that exercise should be taken seriously as part of cancer care. Booth walks through how the study was set up and what it was asking patients to do. Most people did not need a gym routine or a training plan. Walking did most of the work for the group. Some patients kayaked, cross-country skied, swam, or biked. The typical target was 45 to 60 minutes, three or four times a week, at a pace where they were huffing and puffing. The hosts note that this is similar to the kind of exercise advice cardiologists often give for primary and secondary prevention of cardiovascular disease. Booth points out that the intervention was a delta from baseline, not some universal fitness standard. That distinction matters. Most participants were not very active to begin with. People who already did high-level exercise were excluded. At the other end, participants still had to be fit enough to walk on a treadmill for six minutes. They had already been through a hemicolectomy, six months of chemo, and recovery. The discussion then turns to the people who never make it into clinical trials. Booth says very few patients were excluded because they could not meet the criteria. Many more simply were not interested. That is a different kind of filter. It shapes who the trial can speak for. The episode spends time on external generalizability for exactly that reason. Trial participants are often more motivated than the average patient. They are also often younger and have less comorbidity. The result is a discussion that keeps one foot in the clinic and one foot in the methods. It is interested in evidence, but not in pretending evidence appears out of nowhere. The tone stays collegial and a little dry in the way these conversations often do. The research is treated as something to be translated, not just reported. The episode ends up feeling like a practical argument about what medicine might look like when exercise is not an afterthought.

As heard by us

A grounded look at exercise in cancer care and the limits of who trial evidence can represent.

Chris Booth and the hosts treat exercise in cancer care as a practical question, not a slogan. The discussion stays close to what patients might actually do: many in the trial followed a walking program, usually 45 to 60 minutes at a pace that left them huffing and puffing three…

Read the full review in PlayNext →

Why you'd press play

You want the real-world case for exercise after cancer treatment, not a wellness cliche.

Read the full recommendation in PlayNext →
Listen to the show on